Results 71 to 80 of about 5,939 (158)

JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Luciano Ibba, Luigi Gargiulo, Matteo Bianco, Sara Di Giulio, Ruggero Cascio Ingurgio, Angela Alfano, Carlo A. Vignoli, Mario Valenti, Paola Facheris, Chiara Perugini, Alessandra Narcisi, Antonio Costanzo   +11 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, EarlyView.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib

Pediatric Dermatology, EarlyView.
ABSTRACT Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near‐complete resolution of the psoriatic lesions with ...
Grigorios Theodosiou, Åke Svensson
wiley   +1 more source

Bronchiectasis as an Underrecognized Extraintestinal Manifestation of Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Introduction Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the gastrointestinal tract, often presenting with extraintestinal manifestations (EIMs). The most prevalent pulmonary EIM is IBD‐associated bronchiectasis (IBD‐BE), which is often overlooked.
Lynn te Slaa, Josje Altenburg, Mark Löwenberg   +2 more
wiley   +1 more source

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment

Journal of Dermatological Treatment
Background Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives To compare ocular outcomes and conjunctival
Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak   +2 more
doaj   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies

RMD Open
Introduction Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.Methods Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed ...
Bruno Fautrel, Philip J Mease, Arthur Kavanaugh, Tsutomu Takeuchi, Peter C Taylor, Louis Bessette, Ralph Lippe, Tianming Gao, Charles Phillips, Andrew Garrison, Diane Caballero   +10 more
doaj   +1 more source

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026)

Contact Dermatitis, Volume 95, Issue 3, Page 237-275, September 2026.
ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter, Olivier Aerts, Tove Agner, Richard Brans, Magnus Bruze, Alicia Cannavó, Marie‐Noёlle Crépy, Ana M. Giménez‐Arnau, Margarida Gonçalo, An Goossens, Swen M. John, Carola Lidén, Suzana Ljubojević Hadžavdić, Vera Mahler, Mihaly Matura, Esen Özkaya, Maria Pesonen, Nadia Raison‐Peyron, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Ian R. White, S. Mark Wilkinson, Jeanne Duus Johansen   +23 more
wiley   +1 more source

Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy.
André Lucas Ribeiro, Zahra Al‐Zahir, Virginia Carrizo Abarza, Khalad Maliyar, Siddhartha Sood, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar, Dafna D. Gladman, Jensen Yeung, Vinod Chandran, Lihi Eder   +11 more
wiley   +1 more source